Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Adults With Chronic Hepatitis B

NCT07200193 is registered in ClinicalTrials.gov with nChroma Bio as lead sponsor.

NCT NCT07200193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07200193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Adults With Chronic Hepatitis B
Lead sponsor
nChroma Bio
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 22, 2025
Completion date
December 31, 2032
Enrollment
66 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepaititis b